Futures studies should also analyze UFM1 and UFSP2 in non-tau neurodegenerative diseases such as frontotemporal dementia and Lewy body disease to test whether the UFMylation changes are specific for AD or for tauopathies in general. This evidence concerns the gene UFM1 and Lewy body dementia.